Bayer receives FDA priority review for copanlisib to treat follicular lymphoma

German drug manufacturer Bayer has received priority review designation for the new drug application (NDA) for copanlisib from the US Food and Drug Administration (FDA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news